Stockscreener 앱 받기
6.435
1.82%
0.115
시간 외 거래:
6.40
-0.035
-0.54%
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
Prothena announces 63% workforce reduction following birtamimab halt - Investing.com
Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus
Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus
Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks
Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus
Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus
Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus
Prothena to cut workforce by 63% amid strategic review - Investing.com
Prothena announces corporate restructuring - MarketScreener
Prothena Announces Corporate Restructuring - Business Wire
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey
(PRTA) Trading Signals - news.stocktradersdaily.com
Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks
Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com
Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus
Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa
Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com
Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World
Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World
Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
(PRTA) Technical Data - news.stocktradersdaily.com
Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
0.68%
0.50%
자본화:
|
볼륨(24시간):